The primary objective of this educational exhibit is to provide an illustrative tutorial to highlight the utility and limitations of [F18]-FDG PET/CT for imaging evaluation of various phases of prostate cancer natural history.
The major teaching points of this exhibit are:
1. FDG PET/CT is a powerful asset to the currently available imaging modalities for evaluating prostate cancer.
2. FDG PET/CT is useful in diagnosis and staging of high Gleason score primary tumors, in detection of locally recurrent and/or metastatic disease in a portion of men with PSA relapse, in monitoring response to androgen deprivation and chemotherapy, and in prognostication.
I. Brief literature review
II. Diagnostic utility:
a) Evaluation of cancer localized to the prostate gland and surgical bed
b) Evaluation of lymph node and soft tissue metastases
c) Evaluation of skeletal metastases
III. Response assessment utility:
a) Response to hormonal therapy for castrate-sensitive disease
b) Response to chemotherapy for castrate-resistant disease
IV. Prognostic utility:
a) Castrate-sensitive --> Castrate-resistant disease
b) Castrate-resistant disease --> Death
V. Comparing PERCIST (PET-based) response assessment criteria to well establihsed and widely used RECIST and PSA-based response assessment criteria.
Desai, B,
Jadvar, H,
The Utility of [F18]-Fluorodeoxyglucose PET/CT for Imaging Prostate Cancer: A Pictorial Guide. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL.
http://archive.rsna.org/2014/14014082.html
